
STATUTORY INSTRUMENTS

2019 No. 791

**The Medical Devices (Amendment
etc.) (EU Exit) Regulations 2019**

PART 1

Amendment of the 2002 Regulations

Amendment of Part VII of the 2002 Regulations

- 9.—(1) Part VII of the 2002 Regulations is amended as follows.
- (2) In regulation 59^{M1}(interpretation of Part VII)—
- (a) omit the definition of “registrable device”;
 - (b) in the definition of “relevant device” after “IV” insert “ or a device for the purposes of Part VIII or IX. ”.
- (3)^{M2}In regulation 60 (designation etc. of authorised representatives)—
- (a) for the heading substitute “ Status of UK responsible person ”;
 - (b) omit paragraphs (1) and (2);
 - (c) for paragraph (3), substitute—
 - “(3) A UK responsible person—
 - (a) may be proceeded against as a person placing the device on the market for the purposes of these regulations;
 - (b) in relation to the supply of the device to a person within the United Kingdom after it has been placed on the market, may be proceeded against as a person supplying the device after it has been placed on the market.”.
- [^{F1}(d) in paragraph (4)—
- (i) for “an authorised representative of a manufacturer of a device” substitute “ a UK responsible person ”;
 - (ii) for “the single authorised representative of the manufacturer” substitute “ a UK responsible person ”.]
- [^{F2}(4) In regulation 61 (enforcement etc.)—
- (a) for “CE marking” in both places substitute “UK marking”;
 - (b) in paragraph (8)(a)(i), after “essential requirement” insert “, a general safety and performance requirement”;
 - (c) in paragraph (8)(a)(ii), omit “set out in the Medical Devices Directives”;
 - (d) in paragraph (8)(a)(ii)(aa), for “his authorised representative” substitute “their UK responsible person”.]
- (5) In regulation 62 (compliance notices) in paragraph (1)—

- (i) after “performance evaluation” insert “ or study ”;
- (ii) for “the manufacturer or his authorised representative” substitute “ any person ”;
- [^{F3}(iii) in sub-paragraph (c) omit “and, where applicable any relevant provision of the Medical Devices Directives”.]
- (6) In regulation 63 ^{M3} (restriction notices) in paragraph (1)—
 - (i) in sub-paragraph (a), after “performance evaluation” insert “ or study ”;
 - (ii) in sub-paragraph (b), after “performance evaluation” insert “ or study ”.
- [^{F4}(6A) In regulation 64 (notification of decisions etc)—
 - (a) in paragraph (1)(c), for “him or his authorised representative” substitute “the applicant or the applicant’s UK responsible person”;
 - (b) in paragraph (2)—
 - (i) for “a UK notified body” substitute “an approved body”;
 - (ii) for “his authorised representative” substitute “their UK responsible person”.]
- (7) Omit regulation 65(centralised system of records etc.).
- (8) In regulation 67 ^{M4} (review), for “2019” substitute “ 2025 ”.
- (9) Omit Schedule 1 ^{M5} (association agreements).
- (10) For Schedule 2 ^{M6} (mutual recognition agreements) substitute—

“SCHEDULE 2

Regulation 1A

Mutual Recognition Agreement countries

- Australia
- New Zealand
- Canada
- The United States of America
- The Swiss Confederation”.

Textual Amendments

- F1** Reg. 9(3)(d) substituted (31.12.2020 immediately before IP completion day) by [The Human Medicines and Medical Devices \(Amendment etc.\) \(EU Exit\) Regulations 2019 \(S.I. 2019/1385\), reg. 1, Sch. 2 para. 8; 2020 c. 1, Sch. 5 para. 1\(1\)](#)
- F2** Reg. 9(4) substituted (31.12.2020 immediately before IP completion day) by [The Medical Devices \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1478\), reg. 1\(3\), Sch. 2 para. 51](#)
- F3** Reg. 9(5)(iii) inserted (31.12.2020 immediately before IP completion day) by [The Medical Devices \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1478\), reg. 1\(3\), Sch. 2 para. 52](#)
- F4** Reg. 9(6A) inserted (31.12.2020 immediately before IP completion day) by [The Medical Devices \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1478\), reg. 1\(3\), Sch. 2 para. 53](#)

Commencement Information

- I1** Reg. 9(1)(3)-(10) in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, [Sch. 5 para. 1\(1\)](#)), see [reg. 1\(1\)](#)
- I2** Reg. 9(2) in force at 1.5.2021, see [reg. 1\(2\)\(e\)](#) (as amended by [S.I. 2020/1478, reg. 1\(3\), Sch. 2 para. 2\(c\)](#))

Marginal Citations

- M1** Regulation 59 was amended by [S.I. 2003/1697](#).
- M2** Regulation 60 was amended by [S.I. 2008/2936](#).
- M3** Regulation 63 was amended by [S.I. 2008/2936](#).
- M4** Regulation 67 was inserted by [S.I. 2013/2327](#).
- M5** Schedule 1 was amended by [2013/2327](#).
- M6** Schedule 2 was amended by [S.I. 2013/2327](#).

Changes to legislation:

There are currently no known outstanding effects for the The Medical Devices (Amendment etc.) (EU Exit) Regulations 2019, Section 9.